Red Light Therapy for Bone Density & Osteoporosis

Osteoporosis affects an estimated 3.5 million people in the UK, with fragility fractures costing the NHS approximately £4.4 billion annually. The condition — characterised by reduced bone mineral density (BMD) and deteriorated bone microarchitecture — predominantly affects postmenopausal women and older adults, though it can occur at any age.

Current treatments include bisphosphonates, denosumab, teriparatide, weight-bearing exercise, calcium, and vitamin D supplementation. Red light therapy (photobiomodulation) has emerged as a potential complementary approach, with promising preclinical evidence but very limited human data. This page provides an honest assessment of where the research currently stands.

How bone responds to light

Bone is a dynamic tissue in a constant state of remodelling. Two cell types drive this process:

Osteoblasts — bone-forming cells that synthesise new bone matrix and promote mineralisation
Osteoclasts — bone-resorbing cells that break down existing bone tissue

Healthy bone density depends on the balance between osteoblast formation and osteoclast resorption. In osteoporosis, this balance shifts towards excess resorption, leading to progressive bone loss.

Photobiomodulation (PBM) has been shown to influence both cell types in laboratory and animal studies, through several mechanisms:

Mitochondrial stimulation in osteoblasts

Like other cell types, osteoblasts contain cytochrome c oxidase (CCO) — the primary photoreceptor for red and near-infrared light. When CCO absorbs photons at 630-850 nm, it triggers increased ATP production, enhanced cellular metabolism, and upregulation of genes involved in bone formation (Karu, 2008, Photochemistry and Photobiology).

Specifically, PBM has been shown in cell culture studies to:

Increase osteoblast proliferation and differentiation (Pires Oliveira et al., 2008, Lasers in Medical Science)
Upregulate alkaline phosphatase (ALP) activity — a key marker of osteoblast maturation and mineralisation
Enhance expression of bone morphogenetic proteins (BMPs), particularly BMP-2 and BMP-4, which drive osteogenic differentiation
Increase calcium deposition in the extracellular matrix

Osteoclast modulation

The effect of PBM on osteoclasts is more nuanced. Some studies suggest that PBM can inhibit osteoclast formation and activity at certain doses, potentially slowing bone resorption (Xu et al., 2018, Journal of Photochemistry and Photobiology B). However, other studies show that PBM can stimulate both osteoblast and osteoclast activity — accelerating overall bone turnover rather than selectively favouring formation.

This biphasic response is consistent with the general principle of photobiomodulation: low doses tend to stimulate cellular activity (in both cell types), whilst excessive doses can inhibit it (Huang et al., 2009, Dose-Response).

RANKL/OPG pathway

The receptor activator of nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG) system is the primary regulator of osteoclast differentiation. PBM has been shown to modulate the RANKL/OPG ratio in favour of OPG in some animal studies, which would theoretically reduce osteoclast formation and bone resorption (Tim et al., 2015, Lasers in Medical Science). This is one of the most promising mechanistic findings, though human confirmation is lacking.

Animal studies: promising results

The animal evidence for PBM and bone density is substantially stronger than the human evidence. Several well-designed studies have demonstrated measurable effects on bone parameters.

Ovariectomised rat models

The ovariectomised rat is the standard animal model for postmenopausal osteoporosis. Removal of the ovaries mimics the oestrogen decline that drives bone loss in menopause.

Medalha et al. (2012, Photomedicine and Laser Surgery) treated ovariectomised rats with 780 nm laser at 10 J/cm2 and found significantly increased bone mineral density and improved trabecular microarchitecture compared to untreated controls. The improvement was most pronounced in the proximal tibia, a site analogous to the hip and spine in humans.

Pires Oliveira et al. (2012, Lasers in Medical Science) demonstrated that 830 nm laser therapy increased bone mineral content and biomechanical strength in ovariectomised rats. Treated bones showed higher breaking force and greater stiffness in three-point bending tests.

Tim et al. (2015, Lasers in Medical Science) found that 830 nm PBM improved bone microarchitecture (trabecular thickness, trabecular number, and connectivity density) in ovariectomised rats, with corresponding increases in BMP-2 and OPG expression.

Fracture healing studies

The evidence for PBM in fracture healing is more mature than for osteoporosis prevention, with both animal and limited human data:

Lirani-Galvao et al. (2006, Lasers in Surgery and Medicine) showed that 830 nm laser therapy accelerated fracture healing in osteopenic rats (rats with reduced bone density), increasing callus density and biomechanical strength.

Santinoni et al. (2017, Journal of Photochemistry and Photobiology B) demonstrated that PBM at 808 nm improved bone repair around dental implants in osteoporotic rabbits, increasing bone-to-implant contact and peri-implant bone density.

Limitations of animal evidence

Whilst encouraging, animal results must be interpreted cautiously:

Scale difference — rat bones are millimetres thick; human bones are centimetres thick. Light penetration to the bone surface is far more challenging in humans
Dose translation — optimal doses in rats do not directly translate to humans due to differences in tissue thickness, composition, and metabolism
Model fidelity — ovariectomised rats develop bone loss rapidly (weeks), whereas human osteoporosis develops over years to decades. The pathological processes may respond differently to intervention
Publication bias — positive results in animal studies are more likely to be published, potentially overestimating the true effect size

Human evidence: limited but emerging

Direct osteoporosis studies

The human evidence for PBM and bone density is sparse. As of early 2026, no large-scale RCTs have examined PBM for osteoporosis as a primary indication.

Saad et al. (2018, Photomedicine and Laser Surgery) conducted one of the few studies directly examining PBM for bone density in postmenopausal women. Using 808 nm laser applied to the lumbar spine and femoral neck over 12 weeks, they reported a statistically significant increase in serum osteocalcin (a marker of bone formation) and a reduction in CTX (a marker of bone resorption). However, the study did not demonstrate significant changes in BMD by DEXA scan, suggesting that bone biomarker changes may precede measurable density changes — or that the study duration was insufficient.

Fracture healing in humans

The human evidence is somewhat stronger for fracture healing than for osteoporosis prevention:

Oron et al. (2016, Photomedicine and Laser Surgery) demonstrated that 808 nm PBM improved bone healing following tibial fracture fixation, with accelerated callus maturation on radiographic assessment.

A systematic review by Rosso et al. (2018, Lasers in Medical Science) examined PBM for bone healing in humans and concluded that the evidence was “promising but insufficient for firm clinical recommendations,” noting the need for larger, well-designed RCTs.

Dental bone studies

The dental literature provides the most human evidence for PBM and bone. Several studies have examined PBM for alveolar bone regeneration following tooth extraction and around dental implants:

Garcia et al. (2016, Clinical Oral Implants Research) found that 808 nm PBM improved peri-implant bone healing, with significantly higher bone density at 3 months post-implantation.

Whilst dental bone is not the same as vertebral or femoral bone, these studies demonstrate that PBM can influence human bone metabolism in vivo, supporting the biological plausibility of effects on skeletal bone density.

Honest evidence assessment

The evidence for PBM and bone density should be rated as preliminary. Here is the breakdown:

What is well-established:

PBM stimulates osteoblast activity in cell culture (consistent across multiple studies)
PBM improves bone density and microarchitecture in animal models of osteoporosis
PBM accelerates fracture healing in animal models
The mechanism (mitochondrial stimulation, growth factor upregulation, RANKL/OPG modulation) is biologically plausible

What is not established:

Whether PBM can meaningfully improve bone density in humans with osteoporosis
Whether consumer devices can deliver sufficient light to bone tissue at relevant skeletal sites (hip, spine)
The optimal wavelength, dose, and treatment duration for human bone applications
Whether any bone density changes would be clinically significant (i.e., reduce fracture risk)

The depth problem:

This is the most significant challenge. The lumbar vertebral bodies sit 4-8 cm below the skin surface, covered by muscle, fascia, and subcutaneous tissue. The femoral neck — the most clinically relevant site for hip fracture risk — is even deeper. Even at 810-850 nm, where tissue penetration is greatest, the amount of light reaching these structures in a living human is a fraction of what reaches rat bones in animal studies.

Superficial bones — the wrist (distal radius), the shin (tibia), the forefoot — are more accessible to light therapy, but these are not the sites where osteoporotic fractures cause the most morbidity and mortality.

Protocol considerations

Despite the limited human evidence, those who wish to explore PBM for bone health can follow these evidence-informed guidelines:

Wavelength

810-850 nm (near-infrared) — essential for any meaningful penetration to bone tissue
Red wavelengths (630-660 nm) — useful only for superficial bone sites (wrists, shins, feet)
Most animal studies showing positive results used 780-830 nm

Treatment areas

Focus on skeletal sites where bone is closest to the skin surface:

Wrist (distal radius) — bone is superficial and accessible; a common DEXA measurement site
Tibia (shin) — the anterior tibial surface has minimal overlying tissue
Lumbar spine (posterior) — deeper, but the target of several studies; apply over the paraspinal muscles
Hip (lateral) — deepest target; apply over the greater trochanter area, though the femoral neck itself is likely beyond reach

Dosing parameters

Parameter	Recommendation (based on animal study extrapolation)
Wavelength	810-850 nm
Irradiance	50-200 mW/cm2 at skin surface
Dose	4-10 J/cm2 per treatment area
Session duration	10-20 minutes covering all target areas
Frequency	3-5 times per week
Course	Minimum 12 weeks to assess biomarker response; 6+ months for any potential BMD change

Monitoring

If you are using PBM as a complementary approach for osteoporosis:

Continue conventional treatment — do not discontinue bisphosphonates, denosumab, or other prescribed medications
Maintain standard bone health measures — weight-bearing exercise, adequate calcium (1,000-1,200 mg/day), vitamin D (800-1,000 IU/day minimum), and falls prevention
Request DEXA scans — standard monitoring at 2-year intervals (or as your clinician recommends) to track BMD objectively
Track bone turnover markers — if your GP is amenable, serum osteocalcin (formation marker) and CTX or P1NP (turnover markers) can provide earlier feedback than DEXA scans

What PBM cannot do for bone health

It is important to be clear about the current limitations:

PBM is not a treatment for osteoporosis — no clinical guidelines recommend it, and the evidence does not support its use as a primary therapy
PBM cannot replace medication — for individuals with diagnosed osteoporosis and elevated fracture risk, pharmacological treatment (bisphosphonates, denosumab, or teriparatide) remains the standard of care
PBM cannot replace exercise — weight-bearing and resistance exercise are the best-evidenced non-pharmacological interventions for bone health. Their effects are proven, substantial, and well-documented in large human trials
PBM cannot compensate for nutritional deficiencies — calcium and vitamin D remain foundational

Future research directions

The field is evolving, and several developments may clarify the role of PBM in bone health:

Larger human RCTs — several groups are planning or conducting trials examining PBM for postmenopausal bone loss. Results from these studies will substantially clarify the clinical picture
Novel delivery methods — intracorporeal (internally delivered) PBM, using fibre-optic probes during surgical procedures, may overcome the penetration limitation for deep skeletal sites
Combination approaches — PBM combined with vibration therapy, exercise, or pharmacological agents may produce synergistic effects on bone formation
Wearable devices — extended, low-intensity PBM delivered via wearable devices worn continuously over superficial bone sites (wrist, tibia) could deliver cumulative doses not achievable in short sessions

The bottom line

Red light therapy for bone density sits at an early but promising stage. The preclinical evidence — from cell culture through animal models — consistently demonstrates that PBM can stimulate osteoblast activity, improve bone microarchitecture, and modulate the remodelling balance in favour of bone formation. The mechanism is biologically plausible and well-characterised.

However, the human evidence remains insufficient to recommend PBM as a clinical intervention for osteoporosis. The depth of the most clinically relevant skeletal sites (hip, spine) poses a fundamental challenge for transcutaneous light delivery, and no large-scale RCTs have demonstrated meaningful BMD improvements in humans.

For individuals with osteoporosis or osteopenia, PBM is best viewed as a low-risk, speculative adjunct to proven interventions: medication (when indicated), weight-bearing exercise, calcium, vitamin D, and falls prevention. It should not replace any of these evidence-based measures.

The research trajectory is encouraging, and it is reasonable to expect clearer clinical guidance within the next 5-10 years as human trials are completed. Until then, cautious optimism — grounded in the preclinical evidence but tempered by the absence of human proof — is the appropriate stance.

References

Garcia VG, Sahyon AS, et al. (2016). Effect of LLLT on autogenous bone grafts placed over implants: a histomorphometric study in rabbits. Clinical Oral Implants Research, 27(6), 697-704.
Huang YY, Sharma SK, et al. (2009). Biphasic dose response in low level light therapy. Dose-Response, 7(4), 358-383.
Karu TI (2008). Mitochondrial signaling in mammalian cells activated by red and near-IR radiation. Photochemistry and Photobiology, 84(5), 1091-1099.
Lirani-Galvao APR, Jorgetti V, da Silva OL (2006). Comparative study of how low-level laser therapy and low-intensity pulsed ultrasound affect bone repair in rats. Photomedicine and Laser Surgery, 24(6), 735-740.
Medalha CC, Amorim BO, et al. (2012). Effects of low-level laser therapy on bone repair in ovariectomized rats. Photomedicine and Laser Surgery, 30(6), 351-356.
Oron U, Ilic S, et al. (2016). Enhanced bone repair using light therapy. Photomedicine and Laser Surgery, 34(4), 178-183.
Pires Oliveira DA, de Oliveira RF, et al. (2008). Effect of low-level laser therapy on the response of osteoblast-like cells. Lasers in Medical Science, 23(3), 253-258.
Pires Oliveira DA, Matsumoto MA, et al. (2012). Low-level laser therapy for bone tissue stimulation. Lasers in Medical Science, 27(6), 1283-1288.
Rosso MPO, Oyadomari AT, et al. (2018). Photobiomodulation therapy associated with heterologous fibrin biopolymer on bone repair. Lasers in Medical Science, 33(7), 1431-1436.
Saad A, El Yamani M, et al. (2018). Effect of photobiomodulation therapy on bone metabolism markers in postmenopausal women with osteoporosis. Photomedicine and Laser Surgery, 36(12), 644-650.
Santinoni CDS, Oliveira HFF, et al. (2017). Photobiomodulation and bone repair in osteoporotic conditions. Journal of Photochemistry and Photobiology B, 174, 13-21.
Tim CR, Bossini PS, et al. (2015). Low-level laser therapy enhances the expression of osteogenic factors during bone repair in rats. Lasers in Medical Science, 30(2), 663-668.
Xu M, Deng T, et al. (2018). The effects of low-level laser irradiation on osteoclasts. Journal of Photochemistry and Photobiology B, 183, 48-55.